Zymeworks (ZYME) News Today

Zymeworks Inc. (NASDAQ: ZYME) has received bullish analyst coverage and a boost from a milestone payment, but sharp reductions to one analyst’s earnings forecasts may be weighing on sentiment.

• Positive Sentiment: Citizens JMP raised its price target to $39 from $32 and reiterated a “market outperform” rating, signaling confidence in Zymeworks’ prospects. Tickerreport article
• Positive Sentiment: A milestone payment helped lift the outlook after a profitable quarter; coverage also cited better-than-expected earnings and the stock reaching a 52-week high. Separate reports noted price-target increases from TD Cowen and a positive outlook from Truist. Yahoo Finance article TD Cowen article Truist article
• Negative Sentiment: HC Wainwright substantially cut its earnings forecasts across several quarters. Most notably, it lowered its FY2027 estimate from $1.32 per share to a loss of $0.39, and reduced its FY2026 estimate from $1.51 to $1.19. The revisions raise concern that recent profitability may not persist, despite the firm keeping its “Buy” rating and $56 target. MarketBeat Zymeworks coverage